Silence Therapeutics looks to be in a strong position to compete among a wave of RNA-based therapies targeting lipoprotein(a) (Lp(a) and may even emerge with a best-in-class molecule that is already generating interest from potential big pharma partners.
Silence Therapeutics Could Rival Amgen And Novartis With siRNA Therapy
Early Results Attract Big Pharma Interest
The UK biotech could have a major gene silencing drug on its hands but will need a big pharma partner to help it realize the candidate’s potential.
